Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PDE2A | O00408 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 9/20 | 0.49 |
| ▸ | PYGM | P11217 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12827225 | 0.85 | KDM4E (0.64) | KDM4EMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17149886 | 0.84 | KMT2A (0.56) | ADRB2KDM4EMEN1KMT2ARCE1 | |
| SCHEMBL17149620 | 0.84 | TP53 (0.64) | ADRB2KDM4EMEN1KMT2ARCE1 | |
| SCHEMBL19476075 | 0.83 | MEN1 (0.64) | KDM4EMEN1KMT2ARCE1NPC1 | |
| SCHEMBL17149629 | 0.83 | MEN1 (0.64) | KDM4EMEN1KMT2ARCE1NPC1 | |
| SCHEMBL6883379 | 0.83 | MEN1 (0.64) | KDM4EMEN1KMT2ARCE1NPC1 | |
| SCHEMBL17149666 | 0.83 | PYGL (0.60) | KDM4EMEN1KMT2ARCE1NPC1 | |
| SCHEMBL17149864 | 0.83 | PYGL (0.63) | MEN1KMT2ANPC1RAB9APYGL | |
| SCHEMBL17149617 | 0.83 | PYGL (0.63) | MEN1KMT2ANPC1RAB9APYGL | |
| SCHEMBL17149890 | 0.83 | PYGL (0.60) | KDM4EMEN1KMT2ARCE1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | ADRB2 143/4885KDM4E 556/4885MEN1 3590/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | ADRB2 125/4885KDM4E 570/4885MEN1 3708/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | ADRB2 125/4885KDM4E 570/4885MEN1 3708/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | ADRB2 148/4885KDM4E 537/4885MEN1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.